Bicara Therapeutics Inc. (BCAX) is a pre-revenue clinical-stage biopharmaceutical company with a single product candidate, ficerafusp alfa, in active Phase 2/3 development. Under the liquidation lens, recovery to equity is entirely dependent on the realizable value of liquid financial assets — principally cash and short-term investments — net of all obligations at face value. The MFFAIS system reports a current liquidation value (cash/liquid/operating, all identical) of approximately $67.1 million as of March 31, 2026. This figure reflects the post-February 2026 capital raise: in February 2026 the company completed an underwritten offering of 8,581,250 shares of common stock plus pre-funded warrants for 2,200,000 shares at $16.00 per share, generating net proceeds of approximately $161.8 million. That capital injection materially replenished the liquidity position relative to the prior year-end balance sheet, which showed total assets of roughly comparable scale prior to the raise. However, the Q1 2026 period-end liquidation value of $67.1 million implies the company consumed approximately $94 million of that raise within the quarter when combined with prior-period cash levels, consistent with the annual cash burn rate of approximately $138 million recorded in fiscal year 2025 (net loss $138.0 million; interest income of $17.9 million indicates a gross burn of approximately $155 million in operating outflows). Intangible assets — patent licenses, know-how, and in-process R&D — receive a zero haircut under liquidation methodology and contribute nothing to recovery. The company has no inventory, no accounts receivable, and no material tangible fixed assets to haircut. All balance sheet value is concentrated in financial instruments (cash, short-term investments) which receive a 100% recovery rate. The liability stack consists of accrued clinical and manufacturing obligations — including accrued IQVIA CRO expenses of $8.6 million as of December 31, 2025, related-party Syngene payables of $3.4 million, and operating lease obligations — all of which survive at face value in a wind-down scenario. The XBRL tag context provided for this filing is empty; no tagged financial data was supplied for the Q1 2026 10-Q period. Accordingly, the $67.1 million liquidation value from MFFAIS metadata is the operative figure. That number represents residual equity recovery after settling all stated obligations, and given the company's quarterly burn rate of approximately $35-40 million, this runway extends roughly 1.5-2 quarters absent additional financing. The filing discusses material off-balance-sheet commitments — including the FORTIFI-HN01 Phase 2/3 trial with IQVIA (initial upfront payments of $12.8 million committed in December 2024) and ongoing Syngene manufacturing obligations extending through 2027-2031 — in MD&A but these are not separately tagged in XBRL in the TAG_CONTEXT provided. CRO termination provisions allow counterparties to exit on material breach or if the company is liquidated, which would accelerate wind-down costs. The net deferred tax asset is fully offset by a $97.8 million valuation allowance as of December 31, 2025 and contributes zero to liquidation recovery.
▼ Community Notes